Zimmer Biomet Holdings, Inc. with ticker code (ZBH) now have 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $160.00 and $112.00 calculating the mean target price we have $136.44. Now with the previous closing price of $113.34 and the analysts are correct then we can expect a percentage increase in value of 20.4%. The day 50 moving average is $120.53 and the 200 day MA is $118.77. The company has a market capitalization of 23.22B. The stock price for the company is currently $112.88 USD
The potential market cap would be $27,955,603,910 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 24.49, revenue per share of $35.89 and a 4.44% return on assets.
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.
